Press Releases Novartis AG Nyse

Equities

NVS

US66987V1098

Real-time Estimate Cboe BZX Other stock markets 11:18:04 2024-04-30 am EDT			5-day change	1st Jan Change
97.24 ^USD	+0.15%		+0.19%	-3.48%

05:01pm	FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	MT
01:00pm	Peptidream Announces Expansion of Peptide Discovery Collaboration with Novartis	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Novartis : Q1 2024 impact and sustainability update	11:08am	PU
European Commission authorises one of first ustekinumab biosimilars in Europe	Apr. 26	AQ
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	Apr. 24	GL
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	Apr. 23	AQ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	GL
Novartis: Q1 Earnings Snapshot	Apr. 23	AQ
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised	Apr. 23	GL
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis	Apr. 17	GL
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)	Apr. 15	GL
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	Apr. 12	AQ
MorphoSys Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis	Apr. 12	AQ
Novartis tender offer for MorphoSys AG commences	Apr. 11	GL
Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2	Apr. 10	AQ
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting	Apr. 06	GL
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis under HSR Act	Mar. 25	AQ
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)	Mar. 22	GL
FDA Approves Sandoz Denosumab Biosimilars	Mar. 18	AQ
Invitation to MorphoSys Full Year Results 2023 Conference Call on March 14, 2024	Mar. 08	AQ
Sandoz granted novel biosimilars approval	Mar. 06	AQ
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting	Mar. 06	AQ